MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$7,097K
Free Cash flow
-$9,476K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Proceeds from issuance of pre-fu...
    • Maturity of investments
    • Others
Negative Cash Flow Breakdown
    • Change in the fair value of warr...
    • Net loss
    • Change in the fair value of prom...
    • Others
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-2,676
-10,760
-7,804
-10,998
Stock-based compensation expense
1,101
622
625
1,724
Depreciation
14
5
12
29
Change in the fair value of warrant liability
-6,700
5,400
1,600
-1,777
Transaction costs associated with warrants
-
0
0
0
Change in the fair value of promissory note
-500
800
400
-423
Promissory note issuance costs
0
0
-1
-335
Gain on sale of equipment
31
-
-
-
Accretion of discount on short-term investments
4
38
89
218
Change in unrealized losses on investments
-
1
-
-
Prepaid expenses, other current and non-current assets
337
-255
-292
11
Accounts payable
-113
44
-796
-88
Accrued expenses and other liabilities
-230
-1,179
981
-121
Net cash used in operating activities
-9,476
-4,852
-4,778
-11,548
Purchase of investments
0
496
1,480
13,940
Maturity of investments
1,500
7,650
5,000
12,845
Purchases of property and equipment
0
6
8
14
Proceeds from sale of fixed assets
42
-
-
-
Net cash provided by (used in) investing activities
1,542
7,148
3,512
-1,109
Proceeds from issuance of common stock
12,000
0
0
8
Proceeds from exercise of stock options
-
0
25
0
Proceeds from issuance of pre-funded warrants
3,000
-
-
-
Proceeds from issuance of promissory note, net
0
0
0
9,664
Proceeds from issuance of common stock from atm facility, net of issuance costs
31
3,754
793
968
Net cash provided by financing activities
15,031
3,754
818
10,640
Net increase (decrease) in cash and cash equivalents
7,097
6,050
-448
-2,017
Cash and cash equivalents at beginning of period
11,520
5,470
7,935
-
Cash and cash equivalents at end of period
18,617
11,520
5,470
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock$12,000K (149900.00%↑ Y/Y)Proceeds from issuance ofpre-funded warrants$3,000K Proceeds from issuance ofcommon stock from atm...$31K (-96.80%↓ Y/Y)Maturity of investments$1,500K (-88.32%↓ Y/Y)Proceeds from sale offixed assets$42K Net cash provided byfinancing activities$15,031K (41.27%↑ Y/Y)Net cash provided by(used in) investing...$1,542K (239.04%↑ Y/Y)Net increase(decrease) in cash and cash...$7,097K (451.86%↑ Y/Y)Canceled cashflow$9,476K Stock-based compensationexpense$1,101K (-36.14%↓ Y/Y)Depreciation$14K (-51.72%↓ Y/Y)Net cash used inoperating activities-$9,476K (17.94%↑ Y/Y)Canceled cashflow$1,115K Change in the fair valueof warrant...-$6,700K (-277.04%↓ Y/Y)Net loss-$2,676K (75.67%↑ Y/Y)Change in the fair valueof promissory note-$500K (-18.20%↓ Y/Y)Prepaid expenses, othercurrent and non-current...$337K (2963.64%↑ Y/Y)Accrued expenses andother liabilities-$230K (-90.08%↓ Y/Y)Accounts payable-$113K (-28.41%↓ Y/Y)Gain on sale ofequipment$31K Accretion of discount onshort-term investments$4K (-98.17%↓ Y/Y)

CalciMedica, Inc. (CALC)

CalciMedica, Inc. (CALC)